Who Paid My Doc
David Franz
Neurology with Special Qualifications in Child Neurology Cincinnati, OH Medical Doctor
NPI 1649204207 CMS profile 1178636
3333 Burnet Ave, Ml 2015, Cincinnati, OH 45229
General payments
$3,636
Research payments
$10,779
Ownership & investment interest
$0
Research they led as principal investigator
$85,525
Through program year 2021, David Franz of Cincinnati, OH is reported in the CMS Open Payments database as having received $3,636 across 6 general payments and $10,779 in research payments paid to them. Separately, studies naming them as principal investigator received $85,525 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $2,512 | 3 | |
| 2020 | General | $1,124 | 3 | |
| 2019 | Research | $10,779 | 1 |
Beside peers
- David Franz
- Neurology with Special Qualifications in Child Neurology median
- Middle half of Neurology with Special Qualifications in Child Neurology
- National median
In program year 2025, general payments to David Franz were reported at $0. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.
Show as a table
| Year | David Franz | Neurology with Special Qualifications in Child Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $262 | $68–$1,313 | $163 |
| 2020 | $1,124 | $188 | $46–$1,222 | $114 |
| 2021 | $2,512 | $183 | $45–$1,356 | $132 |
| 2022 | $0 | $229 | $72–$1,177 | $149 |
| 2023 | $0 | $269 | $93–$1,195 | $160 |
| 2024 | $0 | $300 | $98–$1,428 | $164 |
| 2025 | $0 | $276 | $87–$1,522 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 62 drugsPart D claims
1,968
Drug cost
$2,402,680
Branded share of claims
39.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Epidiolex Cannabidiol (Cbd) | Brand | 159 | $707,289 | |
| Xcopri Cenobamate | Brand | 135 | $319,505 | |
| Afinitor Everolimus | Brand | 12 | $234,596 | |
| Vigabatrin | Generic | 37 | $229,386 | |
| Fintepla Fenfluramine Hcl | Brand | 11 | $158,205 | |
| Topamax Topiramate | Brand | 30 | $105,999 | |
| Everolimus | Generic | 40 | $89,592 | |
| Aptiom Eslicarbazepine Acetate | Brand | 75 | $89,254 | |
| Nayzilam Midazolam | Brand | 34 | $82,686 | |
| Diacomit Stiripentol | Brand | 14 | $60,186 |
The 10 drugs with the highest cost, of 62 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$5,254
Medicare patients
41
Services billed
83
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Ischemic heart disease | 0% | |
| Atrial fibrillation | 0% | |
| COPD | 0% | |
| Osteoporosis | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology with Special Qualifications in Child Neurology in Ohio
Hope O'Brien
Neurology with Special Qualifications in Child Neurology · Cincinnati, OH
Ajay Gupta
Neurology with Special Qualifications in Child Neurology · Cleveland, OH
Anne Connolly
Neurology with Special Qualifications in Child Neurology · Columbus, OH
Tracy Glauser
Neurology with Special Qualifications in Child Neurology · Cincinnati, OH
Cuixia Tian
Neurology with Special Qualifications in Child Neurology · Cincinnati, OH
Aaron Abrams
Neurology with Special Qualifications in Child Neurology · Cleveland, OH
Related records
Neurology with Special Qualifications in Child Neurology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Neurology with Special Qualifications in Child Neurology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.